Can this entrepreneur persuade his potential traders that his enterprise actually can change the world?
2 min learn
Unicorn Hunters, the present that gives viewers the chance to speculate immediately into high-growth potential firms, introduced Starton Therapeutics in its third installment.
Starton CEO Pedro Lichtinger describes the corporate as “creating an method to supply folks with most cancers longer, high-quality lives; eliminating or minimizing the horrible unintended effects they expertise every single day by unlocking the complete potential of accepted medicine.”
Within the episode, Lichtinger speaks about one particular therapy the corporate develops to regulate a type of blood most cancers, including that this isn’t the one innovation within the pipeline. A diversified product portfolio lowers dangers in case regulators don’t approve one, or may additionally ship a strong enhance to valuation if all succeed.
Most cancers has hit Lichtinger shut, together with his brother grappling with a sophisticated type of the illness. The entrepreneur is in a race, not solely in the direction of an IPO, however towards time. His dedication is seen all through the episode in addition to his willpower to persuade each potential investor to capitalize an organization that expects to vary the world and, additionally, his family.
The panel of professional traders that Lichtinger faces within the Circle of Cash (from Steve Wozniak to former U.S. Treasurer Rosa Rios) might select to speculate at this stage or dig deeper into the product, the corporate or the chief group earlier than capitalizing the corporate. On the website unicornhunters.com, amongst different sources, extra info is obtainable to each potential investor.
The Unicorn Hunters present offers traders with clear entry to pick out pre-IPO funding alternatives, like Starton Therapeutics, spotlighting firms in search of to achieve the coveted $1 billion valuation.
To search out out what occurs subsequent, you’ll be able to watch Lichtinger’s pitch and the end result right here.